<DOC>
	<DOCNO>NCT01653067</DOCNO>
	<brief_summary>The STORM-trial consist two part . In part I ( dose escalation Temsirolimus ) primary objective establish maximum tolerated dose Temsirolimus combination Rituximab DHAP . Secondary objective prove ability mobilize stem cell patient schedule high dose therapy . In part II ( full target dose ) primary objective evaluate ORR patient relapse diffuse large B cell lymphoma ( DLBCL ) . The secondary objective evaluate progression free survival ( PFS ) , overall survival ( OS ) Toxicity .</brief_summary>
	<brief_title>STORM : Temsirolimus , Rituximab DHAP Relapsed Refractory Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>This multicenter , open label , single arm , phase II study . There placebo usage within trial . In part I , dose escalation part , trial 6 patient include dose level . There 4 cohort , administer maximum 4 cycle 25 mg , 50 mg , 75mg 100mg Temsirolimus combination Rituximab DHAP . Treatment regimen part I : Part I - Cohort A , B , C , D , X Temsirolimus 25 ( A ) , 50 ( B ) , 75 ( C ) ,100 ( D ) 15 ( X ) mg , Day 1 , 8 , Rituximab ( 375 mg/m² day 2 ) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4 ... repeat day 22 , maximum 4 cycle In part I , inclusion 6 patient , patient receive least 1 complete cycle w/o dose limit toxicity enrollment next cohort initiate . In part II trial 40 patient include receive full target dose , establish within part I study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients histologically proven diagnosis diffuse large cell Bcell lymphoma ( DLBCL ) accord World Health Organization classification . Documented relapse progression follow least one treatment maximum 2 prior treatment . Prior treatment must include least 3 cycle anthracycline contain chemotherapy ( e.g . CHOPlike ) Any follow : least 1 measurable tumor mass ( &gt; 1.5 cm x &gt; 1.0 cm ) , involvement organ bone marrow infiltration Subjects 18 year old Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . Adequate bone marrow reserve : Platelets least 75000/µl , absolute neutrophil count least 1500/µl Alanine aminotransferase ( ALT ) &lt; 2.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) &lt; 2.5 x ULN , Total bilirubin &lt; 1.5 x ULN Calculated creatinine clearance ( MDRD ) &gt; 70 mL/min Eastern Cooperative Oncology Group [ ECOG ] performance Status &lt; 3 Female subject must postmenopausal ( least 6 month ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study ; negative serum ßhCG pregnancy test screen Active central nervous System lymphoma . Brain MRI require clinically indicated Pregnancy breast feed woman Lymphoma DLBCL Severe concomitant disease ( e.g . uncontrolled arterial hypertension , heart failure ( NYHA IIIIV ) , uncontrolled diabetes mellitus , pulmonary fibrosis , uncontrolled hyperlipoproteinemia ) Active uncontrolled infection include HIVpositivity , active Hep B C Mental status preclude patient 's compliance Prior treatment Temsirolimus Known CD20 negativity Patients refractory DHAP prior treatment line Prior autologous allogeneic stem cell bone marrow transplantation Peripheral neuropathy neuropathic pain Grade 2 bad Diagnosed treated malignancy NHL except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , DCIS breast , solid tumor curatively treat evidence disease &gt; 5 year Concurrent treatment another investigational agent conduct trial . Concurrent participation nontreatment study exclude Known intolerance Sirolimus derivates , Cytarabine , Cisplatine Rituximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non Hodgkin´s Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Aggressive Lymphoma</keyword>
	<keyword>Aggressive Non Hodgkin´s Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>aNHL</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Torisel</keyword>
	<keyword>Relapsed Non Hodgkin´s Lymphoma</keyword>
	<keyword>Relapsed Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>aggressive NHL</keyword>
	<keyword>B-NHL</keyword>
	<keyword>aggressive B-NHL</keyword>
</DOC>